Eurand N.V. (EURX) Completes Study on Zentase
Eurand N.V. (Nasdaq: EURX) today announced the completion of a gastrointestinal bioavailability study on Zentase(tm), Eurand's lead product candidate for the treatment of exocrine pancreatic insufficiency (EPI). The study was conducted in chronic pancreatitis patients in the U.S.
Eurand N.V., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies.
Create E-mail AlertRelated Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
